CMET-01. EFFICACY AND OUTCOME OF ANTI-PD1 THERAPY IN PATIENTS WITH LUNG CANCER BRAIN METASTASIS

Abstract

BACKGROUND: There is very limited data on the benefit of checkpoint blockade in the lung cancer brain metastasis (LCBM). The only prospective data available is the study consisting of 18 patients with LCBM treated with pembrolizumab. We report our experience of 100 patients having LCBM treated with nivolumab and pembrolizumab. METHODS: After IRB approval, LCBM patients treated with whole-brain radiation therapy (WBRT), surgery, or stereotactic radio-surgery (SRS) and or Anti-PD1 at a single tertiary care institution from 2014-2017 were reviewed. Kaplan-Meier survival analysis with survival plot was used to assess the overall survival (OS). RESULTS: 100 patients with LCBM treated with anti-PD1 therapy were identified. Forty five percent were males, 13% harbored EGFR mutation and 18% had KRAS mutation. Median KPS was 90 (50-100) and the median age of the patient was 61 years (30-81). The median follow up was 6 months, 55% of the patients died. Fifty patients were treated with nivolumab or pembrolizumab at diagnosis of LCBM. The OS of 8.9 months (CI 6.6, 11.2) was observed in that cohort of patients in contrast with the OS of 14.9 months (CI 12.1, 17.6) was observed in 49 patients who received nivolumab or pembrolizumab after the progression of LCBM following the initial treatment with surgery, WBRT, SRS and/or medical therapy. OS for the entire cohort was 12.288 (CI 10.280, 14.297). Further efficacy analysis including response criteria are ongoing and will be presented at the meeting. CONCLUSIONS: Nivolumab or Pemrolizumab are safe and effective in the treatment of LCBM and prospective trials are needed.